Direxion Daily LLY Bull 2X Shares (ELIL) is a leveraged exchange-traded fund (ETF) that seeks daily investment results, before fees and expenses, of 200% of the daily performance of the common stock of Eli Lilly and Company (NYSE: LLY). The fund provides amplified exposure to Eli Lilly's stock price movements through derivative instruments, including swap agreements and futures contracts; it does not invest directly in LLY shares. Direxion Shares ETF Trust, the issuer, offers a broad range of leveraged and inverse ETFs targeting single stocks, sectors, indices, and commodities, with products categorized as daily bull (2X or 3X), bear (inverse 1X to 3X), and sector-specific funds.
Headquartered in Rye Brook, New York, Direxion was established in 1997 as part of Rafferty Asset Management, LLC, and operates globally with primary distribution through major U.S. broker-dealers and financial advisors targeting sophisticated retail and institutional investors. The firm serves markets in the United States, Europe, and Asia-Pacific through listings on exchanges like NYSE Arca. ELIL, launched in 2024, expands Direxion's single-stock leveraged ETF suite, which includes similar 2X bull products for high-profile names such as Tesla (TSLA), Nvidia (NVDA), and MicroStrategy (MSTR).
Recent developments include the launch of ELIL in mid-2024 amid surging interest in single-stock leveraged ETFs following SEC approvals, alongside new 2X bull funds for CrowdStrike (CRWD) and Broadcom (AVGO) in late 2024. In 2025, Direxion announced strategic enhancements to its options overlay strategies across multiple ETFs and partnered with liquidity providers to improve trading efficiency amid volatile markets. No major acquisitions or reorganizations have occurred, but the firm continues expanding its lineup to capture demand from options traders and short-term speculators.